Surrozen (NASDAQ:SRZN) Posts Quarterly Earnings Results, Misses Expectations By $9.92 EPS

Surrozen (NASDAQ:SRZN) released its quarterly earnings data on Monday. The company reported ($11.02) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92), FiscalAI reports. The company had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.47 million.

Surrozen Stock Performance

NASDAQ:SRZN opened at $32.00 on Tuesday. Surrozen has a 52 week low of $11.66 and a 52 week high of $37.83. The company has a fifty day simple moving average of $25.14 and a two-hundred day simple moving average of $25.30.

Analyst Ratings Changes

SRZN has been the topic of several recent analyst reports. Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, October 15th. William Blair assumed coverage on Surrozen in a research report on Thursday, August 20th. They set an “outperform” rating and a $51.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $54.00 price objective (up from $44.00) on shares of Surrozen in a report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Surrozen presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.33.

About Surrozen

Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.